SPX3,630.74-24.30 -0.66%
DIA290.06-2.66 -0.91%
IXIC10,771.79-31.14 -0.29%

Wells Fargo Maintains Overweight on Cabaletta Bio, Lowers Price Target to $4

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $4.

Benzinga · 09/14/2022 07:01
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $4.